Dermatology Times

09/23/2026

📈 NEW DATA: ORKA-001 demonstrated deepening skin clearance through week 28 in patients with moderate to severe plaque psoriasis, with responses continuing after a single dose administered at week 0.

🔗 Read more: https://hubs.li/Q04y7-QL0

Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.

09/23/2026

For Gina Mangin, MPAS, PA-C, one of the most rewarding parts of being a dermatology PA is making a meaningful difference in patients’ lives. 💜

For , she shares what makes her role so rewarding and recognizes the fellow PAs who continue to inspire her.

09/23/2026

📚 JOURNAL DIGEST: Catch up on the latest research shaping dermatology practice in this week’s Journal Digest.

Explore new findings and clinical insights across dermatologic conditions, treatments, and patient care.

🔗 Read more: https://hubs.li/Q04y6J4Y0

This review of the latest dermatological studies includes insights on

09/23/2026

💜 For , Matthew Brunner, MHS, PA-C, gives a special shoutout to the APPs balancing patient care, education, and motherhood.

To the “supermom” APPs doing it all—we see you.

🎥 Watch now: To the Supermom APPs: We See You (https://hubs.ly/Q04y7pTt0)

09/23/2026

📈 NEW DATA: IMVT-1402 did not meet the primary end point in a proof-of-concept trial evaluating the investigational therapy in cutaneous lupus erythematosus.

Despite missing the primary end point, Immunovant reported findings that may help inform future clinical development.

🔗 Read more: https://hubs.ly/Q04y7rLb0

Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.

09/22/2026

💜 For Sarah Vicari, PA-C, being a dermatology APP is about more than medicine—it’s about the relationships built with patients and the impact made along the way.

For , Vicari shares what makes her role meaningful and celebrates the APPs who continue to inspire her.

🎥 Watch now: https://hubs.li/Q04y4Lz20

09/22/2026

💜 NATIONAL APP WEEK: For Jamie Nichole Restivo, MPAS, PA-C, being an APP is about finding purpose in patient care, expanding access to dermatology, and ensuring APP voices are represented across the specialty.

She shares her path to dermatology and what continues to make the profession meaningful.

🔗 Read more: https://hubs.li/Q04y4Kwj0

Jamie Nichole Restivo, MPAS, PA-C, reflects on her path to dermatology, the evolving role of APPs, and the power of collaboration during National APP Week.

09/22/2026

💡 EXPERT INSIGHTS: Alopecia areata care extends beyond hair regrowth.

For , Deann Graham of Alopecia Life discusses realistic treatment expectations, the emotional impact of hair loss, and how clinicians can help patients feel less alone throughout their treatment journey.

🎥 Watch the full interview:
https://hubs.li/Q04y4Kk10

For Alopecia Awareness Month, Deann of Alopecia Life discusses compassion, treatment expectations, and the psychosocial burden of alopecia areata.

09/22/2026

🚨 BREAKING NEWS: The FDA has granted Fast Track designation to QRX003 for peeling skin syndrome, marking the first Fast Track designation for a therapy being developed for the rare genetic skin disorder.

A phase 2/3 study is planned to evaluate the investigational topical therapy in pediatric and adult patients.

🔗 Read more: https://hubs.li/Q04y2jkh0

The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.

09/22/2026

📊 How well do you know the true costs of dermatology practice ownership?

Test your practice management knowledge on staffing, training, growth, collections, and the less-visible expenses that can affect a practice’s financial health.

🔗 Take the quiz: https://hubs.li/Q04y2jmG0

Test your knowledge of the hidden costs, financial metrics, and operational decisions that can shape a dermatology practice.